ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
I-Mab Biopharma Receives FDA IND Clearance for Proprietary CD73 Antibody TJD5
January 23, 2019I-Mab Biopharma announced the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study for TJD5 in patients with advanced solid tumor has cleared the required 30 day review by the U.S. Food and Drug Administration (FDA)...
Pharma Sources Insight January 2025
